Aditxt 11/14/2023 Earnings Report

Aditxt EPS Results

• Actual EPS: -$487,700.00
• Consensus EPS: -$59,900.00
• Beat/Miss: Missed by -$427,800.00
• One Year Ago EPS: N/A

Aditxt Revenue Results

• Actual Revenue: $0.12 million
• Expected Revenue: $0.25 million
• Beat/Miss: Missed by -$130.00 thousand
• YoY Revenue Growth: N/A

Aditxt Announcement Details

• Date: 11/14/2023
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

Aditxt (NASDAQ:ADTX), a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.